Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States

Brachytherapy

Volumn 6, Issue 1, 2007, Pages 2-8

  Frank, Steven J ^a   Grimm, Peter D ^b   Sylvester, John E ^b   Merrick, Gregory S ^c   Davis, Brian J ^d   Zietman, Anthony ^e   Moran, Brian J ^f   Beyer, David C ^g   Roach III, Mack ^h   Clarke, Daniel H ⁱ   Stock, Richard G ^j   Robert Lee, W ^k   Michalski, Jeff M ^l   Wallner, Kent E ^m   Hurwitz, Mark ⁿ   Potters, Louis ^o   Kuban, Deborah A ^a   Prestidge, Bradley R ^p   Vera, Robyn ^b   Hathaway, Shannon ^b   Blasko, John C ^b   more..

^a UNIVERSITY OF TEXAS   (United States)

^b Seattle Prostate Institute   (United States)

^c WHEELING HOSPITAL   (United States)

^d Mayo Clinic College of Medicine   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Chicago Prostate Cancer Center   (United States)

^g Arizona Oncology Services   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ INOVA ALEXANDRIA HOSPITAL   (United States)

^j MOUNT SINAI HOSPITAL   (United States)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Department of Veteran Affairs ^*  (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o New York Prostate Institute   (United States)

^p Texas Cancer Clinic   (United States)

more..

Author keywords

Brachytherapy; Intermediate risk; Prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEALTH SURVEY; HUMAN; MALE; MEDICAL PRACTICE; MONOTHERAPY; NOMOGRAM; PERINEURIUM; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BIOPSY; UNITED STATES;

BIOPSY, NEEDLE; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM INVASIVENESS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 33846599235     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2006.09.004     Document Type: Article

References (26)

1. Ragde H., Blasko J.C., Grimm P.D., et al. Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up. Semin Surg Oncol 13 (1997) 438-443
2. Holm H.H. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol 13 (1997) 431-437
3. Blasko J.C., Wallner K., Grimm P.D., et al. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 154 (1995) 1096-1099
4. Zelefsky M.J., Moughan J., Owen J., et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1053-1061
5. Stone N.N., and Stock R.G. Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep 3 (2002) 201-206
6. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 80 (1997) 442-453
7. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
8. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
9. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
10. Grimm P.B.J., and Sylvester J. Clinical selection issues for permanent seed prostate brachytherapy. J Brachyther Int 17 (2001) 143-152
11. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
12. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 161 (2005) 32-43
13. Merrick G.S., Butler W.M., Galbreath R.W., et al. Biochemical outcome for hormone-naive patients with Gleason score 3 + 4 versus 4 + 3 prostate cancer undergoing permanent prostate brachytherapy. Urology 60 (2002) 98-103
14. Merrick G.S., Butler W.M., Galbreath R.W., et al. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys 52 (2002) 664-673
15. Merrick G.S., Butler W.M., Galbreath R.W., et al. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J 8 (2002) 79-80
16. Butler W.M., and Merrick G.S. Myths and fallacies in permanent prostate brachytherapy. Med Dosim 28 (2003) 155-165
17. D'Amico A.V., Renshaw A.A., Cote K., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. Am J Clin Oncol 22 (2004) 3726-3732
18. Kestin L.L., Goldstein N.S., Vicini F.A., et al. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 168 (2002) 1994-1999
19. Rossi P.J., Clark P.E., Papagikos M.A., et al. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology 67 (2006) 349-353
20. Epstein J.I. The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. Semin Surg Oncol 16 (1998) 124-128
21. D'Amico A.V. Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate cancer. Cancer J 7 (2001) 375-376
22. Potters L., Purrazzella R., Brustein S., et al. The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 749-754
23. D'Amico A.V., Renshaw A.A., Schultz D., et al. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c, 2a: Implications for patient selection for prostate-only therapy. Int J Radiat Oncol Biol Phys 45 (1999) 847-857
24. Herman C.M., Kattan M.W., Ohori M., et al. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer: A multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 25 (2001) 657-660
25. Potters L., Fearn P., and Kattan M.W. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy 1 (2002) 36-41
26. Thomadsen B.R., Rivard M.J., and Butler W.M. Brachytherapy physics second edition. 2nd ed. (2005), Medical Physics Publishing, Madison, WI